Article

Visus Therapeutics launches phase 2 clinical trial for presbyopia treatment

Clinical-stage pharma company announces next step in investigation of BRIMOCHOL to treat presbyopia.


Visus Therapeutics announced today the beginning of its phase 2 clinical trial of BRIMOCHOLTMophthalmic solution currently under investigation for the treatment of presbyopia.

BRIMOCOHOL is a proprietary pupil-modulating eye drop consisting of two pharmaceuticals: carbachol (a cholinergic agent) and brimonidine tartrate (an alpha-2 agonist). A “pinhole effect,” is created by the combination, which sharpens distant and near images while minimizing any side effects. This results in vision clarity for near tasks such as reading or operating a smartphone.

The phase 2 clinical trial consists of a double-masked, randomized crossover study that evaluates the safety and efficacy of two proprietary formulations of BRIMOCHOL in patients with emmetropic phakic and pseudophakic presbyopia, according to a company news release.

Approximately 42 patients are expected to be enrolled, with the primary endpoint targeting the percentage of patients who gain three lines or more in near visual acuity without a loss of distance vision.

Top line data from the trial is expected in mid-2021, the release stated.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
CIME 2025: Neda Shamie, MD, on expanding options in pharmacological presbyopia management
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
© 2025 MJH Life Sciences

All rights reserved.